Low-fodmap diet, antibiotic therapy, and probiotics in the treatment of sibo – synergy or alternative? a critical analysis of clinical guidelines

Small Intestinal Bacterial Overgrowth (SIBO) and Intestinal Methanogen Overgrowth (IMO) represent complex clinical entities characterized by a pathological shift in microbial populations within the small intestine. Despite rapidly expanding clinical research, a practical consensus regarding long-term therapeutic management remains highly fragmented. This comprehensive review evaluates the current state of international clinical guidelines concerning the three primary therapeutic pillars of SIBO: pharmacological antibiotic therapy, restrictive dietary modifications (specifically the low-FODMAP diet), and supplementation with live biotherapeutic products (probiotics). Through a systematic assessment of contemporary updates including guidelines from the American College of Gastroenterology (ACG), the American Gastroenterological Association (AGA), and European consensus group we analyze whether these management models should serve as concurrent, synergistic strategies or represent distinct alternative pathways. While eubiotic antibiotic interventions, predominantly utilizing rifaximin, possess the strongest evidence base for bacterial eradication, the incorporation of restrictive diets and probiotics introduces significant physiological paradoxes. This paper provides a critical clinical analysis of the interactions between these components and their quantitative impact on gut microbiome architecture. Furthermore, it outlines a synchronized, chronological management algorithm designed to minimize therapeutic conflicts, satisfy stringent peer-review requirements, and optimize sustained clinical remission.